169 related articles for article (PubMed ID: 9750496)
1. [Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer].
Akino H; Suzuki Y; Okada K
Nihon Rinsho; 1998 Aug; 56(8):2003-5. PubMed ID: 9750496
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study of tumor markers in prostatic cancer].
Ishihara Y; Fukagai T; Ohta K; Hiromoto Y; Hiramori M; Torii T; Higaki Y; Imamura K
Hinyokika Kiyo; 1990 Apr; 36(4):425-31. PubMed ID: 1696063
[TBL] [Abstract][Full Text] [Related]
3. [Clinical evaluation of tandem PSA for the diagnosis and follow-up of prostate cancer].
Okaneya T; Mizusawa H; Taguchi I; Yoneyama T
Hinyokika Kiyo; 1996 Nov; 42(11):861-7. PubMed ID: 8973936
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of 3 assay kits of prostate specific antigen in serum of prostatic cancer].
Akimoto S; Akakura K; Shimazaki J
Hinyokika Kiyo; 1988 Dec; 34(12):2143-8. PubMed ID: 2467543
[TBL] [Abstract][Full Text] [Related]
5. Ratio of gamma-seminoprotein to prostate-specific antigen for the detection of prostate cancer: its discrimination power could be influenced by the assay methods of PSA and/or gamma-seminoprotein.
Akino H; Suzuki Y; Oyama N; Kanamaru H; Okada K
Int J Urol; 1999 Sep; 6(9):440-5. PubMed ID: 10510889
[TBL] [Abstract][Full Text] [Related]
6. [The significance of free-type PSA and complex-type PSA in patients with prostatic carcinoma--the characteristics of ACS-PSA method compared with that of Delfia- and Eiken-PSA method].
Arai K; Honda M; Hosoya Y; Sumi S; Umeda H; Yoshida K
Rinsho Byori; 1996 Apr; 44(4):345-50. PubMed ID: 8847816
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
8. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
Akimoto S; Akakura K; Shimazaki J
Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
[TBL] [Abstract][Full Text] [Related]
9. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
Wymenga LF; Mensink HJ
Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein].
Yoshiki T; Okada K; Oishi K; Yoshida O
Hinyokika Kiyo; 1987 Dec; 33(12):2044-9. PubMed ID: 2452559
[TBL] [Abstract][Full Text] [Related]
11. [Prostate cancer test and medical reimbursement].
Yamada T
Rinsho Byori; 2001 Oct; 49(10):978-80. PubMed ID: 11769475
[TBL] [Abstract][Full Text] [Related]
12. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
Kuruma H; Egawa S
Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
[TBL] [Abstract][Full Text] [Related]
13. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
Tsuchiya N; Ohyama C; Habuchi T
Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
[TBL] [Abstract][Full Text] [Related]
14. [The significance of serum prostate-specific antigen, gamma-seminoprotein and prostatic acid phosphatase as prostate cancer markers].
Yamaguchi K; Tanaka M; Kitagawa N; Kotake T; Yanagi S; Ito H
Hinyokika Kiyo; 1989 Jun; 35(6):987-91. PubMed ID: 2478006
[TBL] [Abstract][Full Text] [Related]
15. [Molecular forms of prostate-specific antigen and their clinical significance].
Hilz H
Urologe A; 1995 Jul; 34(4):275-82. PubMed ID: 7545841
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
17. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
[TBL] [Abstract][Full Text] [Related]
18. [Value of prostate-specific antigen measurements with newly developed enzyme immunoassay (MARKIT-M PA)].
Arai Y; Onishi H; Oishi K; Takeuchi H; Yoshida O
Hinyokika Kiyo; 1992 Oct; 38(10):1129-34. PubMed ID: 1282772
[TBL] [Abstract][Full Text] [Related]
19. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
[TBL] [Abstract][Full Text] [Related]
20. [Changes in prostatic acid phosphatase, gamma-seminoprotein and prostate specific antigen after endocrine therapy for stage D2 prostate cancer].
Akimoto S; Akakura K; Masai M; Isaka S; Shimazaki J
Hinyokika Kiyo; 1990 Jul; 36(7):783-91. PubMed ID: 1700588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
